Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06819215 | Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 188 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT04872166 | A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer | recruiting | Phase 1 | 112 | Edgewood Oncology Inc.INDUSTRY | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06770296 | The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study | recruiting | Phase 1 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06725082 | Impact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery(ColBreast) | recruiting | Phase 1 | 30 | Peking University People's HospitalOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06222879 | Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 350 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06532812 | TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer(BAH249) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT06633601 | MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer | recruiting | Phase 1 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05019690 | Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 29 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06331169 | Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer | recruiting | Phase 1 | 42 | Fudan UniversityOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06508216 | A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer(COMPASS-TNBC) | recruiting | Phase 1 / Phase 2 | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT04842812 | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors | recruiting | Phase 1 | 40 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT02897700 | A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast(COC-IDCB) | recruiting | Phase 1 | 300 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06202261 | A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 154 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05746897 | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 38 | Hefei TG ImmunoPharma Co., Ltd.OTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06162559 | Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study(TRAIN-4) | recruiting | Phase 1 | 30 | The Netherlands Cancer InstituteOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT05451784 | Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS(TILS001) | recruiting | Phase 1 / Phase 2 | 20 | Fundacio Clinic BarcelonaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06010862 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06121557 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | recruiting | Phase 1 | 24 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06121570 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | recruiting | Phase 1 | 24 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05981001 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 170 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05981014 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 196 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT04020575 | Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) | recruiting | Phase 1 | 69 | Minerva Biotechnologies CorporationINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | recruiting | Phase 1 | 77 | A&G Pharmaceutical Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT04947280 | Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer | recruiting | Phase 1 / Phase 2 | 120 | Fudan UniversityOTHER | 1 | Jul 1, 2021 | clinicaltrials |
| NCT03591276 | Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer(KEYDOX) | recruiting | Phase 1 / Phase 2 | 15 | Shaare Zedek Medical CenterOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT04481763 | A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast | recruiting | Phase 1 / Phase 2 | 20 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jul 22, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Feb 11, 2025source: clinicaltrials